Volume 11, Number 10—October 2005
Research
Community-associated Methicillin-resistant Staphylococcus aureus, Minnesota, 2000–2003
Jessica M. Buck*
, Kathryn Como-Sabetti*, Kathleen H. Harriman*, Richard N. Danila*, David J. Boxrud*, Anita Glennen*, and Ruth Lynfield*
, Kathryn Como-Sabetti*, Kathleen H. Harriman*, Richard N. Danila*, David J. Boxrud*, Anita Glennen*, and Ruth Lynfield*
Table 3
Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) invasive disease patient and skin and soft tissue infection (SSTI) patient isolate characteristics*
| Antimicrobial agent | Invasive disease isolates (n = 57), no. (% susceptible) | SSTI isolates (n = 517), no. (% susceptible) | OR (95% CI) | p value† | p value‡ |
|---|---|---|---|---|---|
| Oxacillin (methicillin) | 0 | 0 | NA | ||
| Ciprofloxacin | 37 (65) | 433 (84) | 3.34 (1.67–6.69) | 0.002 | 0.23 |
| Clindamycin | 44 (77) | 475 (92) | 2.79 (1.54–5.04) | 0.001 | 0.20 |
| Erythromycin | 21 (37) | 201 (39) | 1.09 (0.62–1.92) | ||
| Gentamicin | 56 (98) | 509 (98) | 1.14 (0.14–9.25) | ||
| Linezolid | 57 (100) | 517 (100) | NA | ||
| Mupirocin | 56 (98) | 508 (98) | 1.14 (0.14–9.23) | ||
| Rifampin | 56 (98) | 515 (99) | 4.60 (0.41–51.5) | ||
| Tetracyline | 52 (91) | 469 (91) | 0.94 (0.36–2.46) | ||
| Trimethoprim-sulfamethoxazole | 56 (98) | 514 (99) | 3.06 (0.31–2.99) | ||
| Vancomycin | 57 (100) | 517 (100) | NA |
*OR, odds ratio; CI, confidence interval; NA, not applicable.
†Refers to the probablility that the percentage susceptible for invasive CA-MRSA isolates differed from SSTI CA-MRSA isolates after controlling for sex and age.
‡Refers to the probability that the percentage susceptible for invasive CA-MRSA isolates differed from SSTI CA-MRSA isolates after controlling for sex and pulsed-field type associated with healthcare-associated MRSA or CA-MRSA.
Page created: February 22, 2012
Page updated: February 22, 2012
Page reviewed: February 22, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.